Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio
Shots:
- J&J entered into a definitive agreement to acquire Intra-Cellular Therapies, incl. its drugs Caplyta & ITI-1284, for a total equity value of ~14.6B (cash + debt), with shareholders receiving $132/share in cash, making the latter private
- In Dec 2024, the latter filed an sNDA to the US FDA for Caplyta as adj. therapy for MDD. In addition, 2 P-III trials showed improved depressive symptoms & favorable safety, with additional P-III trials for bipolar I mania underway
- Caplyta (oral, QD) modulates serotonin (5-HT2A) & Dopamine (D2) receptors to treat schizophrenia & bipolar depression while ITI-1284 is in P-II trials for the treatment of GAD & AD related psychosis & agitation
Ref: Johnson & Johnson | Image: Intra-Cellular Therapies
Related News: Johnson and Johnson to Acquire V-Wave, Expanding and Strengthening J&J MedTech Segment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
